http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008008704-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2aa316880948bfc3b06d74762a37ace http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d43068152ff62df7d112456cbae444f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e539f7c4a608aa989e75344fdd00b45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_feb9476d222fb718a42727ff22951eb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_748689e55548f1441272f7a445739985 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-22 |
| filingDate | 2007-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9d49d8305571af04587682f69081409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0783744587523e7236a1dfb7e8958ff1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53de78a44c0b471d2d4ffb613fb04ed9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62c52faa4e8c14645ff94c6ffb4c25dd |
| publicationDate | 2009-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008008704-A3 |
| titleOfInvention | Inhibitors of cyclic nucleotide synthesis and their use for therapy of various diseases |
| abstract | We disclose a method of inhibiting activity of adenylyl cyclase or guanylyl cyclase in a mammal by administering to the mammal an amount of a composition effective to inhibit the activity, wherein the composition contains at least one compound selected from the group consisting of structural formulae (Ia) and (Ib) and salts thereof, wherein R1 is -H or has the structure -C(=O)R8; R2 is =O or has the structure -OC(=O)R9; and R3, R4, R5, R6, and R7 are each independently selected from the group consisting of -H, -NO2, formula (I), -halogen, -OC(=O)R9, -OR9, -OH, -R8OH, -CH3, -OC(=O)CH2Ph, formulae (II), (III), (IV), -OPh, -CF3, -R8, -C(=O)OR9, -Ph, -R8Ph, formulae (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), and (XXI), wherein each R8 is independently a linear or branched hydrocarbon group having from 1 to 4 carbon atoms and each R9 is independently a hydrocarbon group having from 1 to 2 carbon atoms. Administering the composition can be used to treat a disease in a mammal mediated by activity of adenylyl cyclase or guanylyl cyclase and effected by a toxin produced by a pathogenic organism or to reduce cyclic AMP or cyclic GMP levels in a mammal in need of reduction thereof. The composition can also be administered to mammalian cells in vitro. The above methods of inhibiting activity of adenylyl cyclase or guanylyl cyclase and treating diseases via such inhibition can be effective without prolonged treatment, have reversible effects, have low or no toxicity, are highly potent, are unlikely to have side effects, do not act on purinergic receptors, or can negate pathogenic toxins independently of whether the pathogenic organism survives. |
| priorityDate | 2006-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 212.